Cheaper Wegovy, 23andMe shutters, and RFK Jr. cuts FDA jobs: Pharma news roundup
Novo Nordisk is expanding its cash-only savings program offering its blockbuster weight-loss drug Wegovy for $499 a month at all U.S. pharmacies. 23andMe has filed for Chapter 11 bankruptcy protection with CEO Anne Wojcicki stepping down to help with a sale. And the U.S. Department of Health and Human Services (HHS)…Read more... [...]
Rating
Innovation
Pricing
Technology
Usability
We have discovered similar tools to what you are looking for. Check out our suggestions for similar AI tools.
23andMe founder Anne Wojcicki will regain control of embattled DNA company after all
In a surprise twist, 23andMe founder and former CEO Anne Wojcicki is set to regain control of the DNA company's assets, according to a press release from 23andMe. In May, a company called Regener [...]
23andMe has filed for bankruptcy and CEO Anne Wojcicki has stepped down
DNA testing company 23andMe has filed for Chapter 11 bankruptcy, following a tumultuous few years that included significant layoffs and a wide-ranging data breach. It plans to find a buyer and continu [...]
Wegovy's price cut, Amgen's Ozempic competitor, and Big Pharma's tax cut: Pharma news roundup
Novo Nordisk just cut the price of its weight-loss drug, Wegovy, by more than half for patients who pay without insurance. Amgen (AMGN) announced this week that it has begun two late-stage clinical tr [...]
The FDA rolls out its own AI to speed up clinical reviews and scientific evaluations
The FDA has launched the generative AI tool, Elsa, agency-wide to help its employees with everything from clinical reviews to investigations. Sure, we're living in a time of widespread disinforma [...]
23andMe bankruptcy: Can EU and UK laws protect DNA data? Here’s what you need to know
San Francisco-based 23andMe, which sells at-home DNA testing kits, has filed for bankruptcy in the US and is looking for a new buyer — heightening concerns about the personal data of millions of peo [...]
